These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 22516246)

  • 41. The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study.
    Ritsner M; Ponizovsky A; Endicott J; Nechamkin Y; Rauchverger B; Silver H; Modai I
    Eur Neuropsychopharmacol; 2002 Feb; 12(1):31-8. PubMed ID: 11788238
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Associations of Clozapine Use With Psychosocial Functioning and Quality of Life in Patients With Schizophrenia: A Community-Based Cross-Sectional Study.
    Kim S; Kim S; Choe AY; Kim E
    Psychiatry Investig; 2021 Oct; 18(10):968-976. PubMed ID: 34619819
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The real-life effectiveness of psychosocial therapies on social autonomy in schizophrenia patients: Results from a nationwide cohort study in France.
    Ali A; Carre A; Orri M; Urbach M; Barry C; Hassler C; Falissard B; Berthoz S; Nordon C
    Psychiatry Res; 2017 Jan; 247():97-104. PubMed ID: 27886580
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The association between childhood trauma and treatment outcomes in schizophrenia spectrum disorders.
    Kilian S; Asmal L; Phahladira L; Plessis SD; Luckhoff H; Scheffler F; Buckle C; Emsley R
    Psychiatry Res; 2020 Jul; 289():113004. PubMed ID: 32387789
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Meta-analysis of physical activity and effects of social function and quality of life on the physical activity in patients with schizophrenia.
    Ohi K; Kataoka Y; Shimada T; Kuwata A; Okubo H; Kimura K; Yasuyama T; Uehara T; Kawasaki Y
    Eur Arch Psychiatry Clin Neurosci; 2019 Aug; 269(5):517-527. PubMed ID: 29789938
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quality of life: an assessment of the state of psychosocial rehabilitation of patients with schizophrenia in the community.
    Hasanah CI; Razali MS
    J R Soc Promot Health; 2002 Dec; 122(4):251-5. PubMed ID: 12557735
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study.
    Swartz MS; Wagner HR; Swanson JW; Stroup TS; McEvoy JP; McGee M; Miller DD; Reimherr F; Khan A; Cañive JM; Lieberman JA
    Psychiatr Serv; 2006 Aug; 57(8):1110-6. PubMed ID: 16870961
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative study of quality of life and metabolic syndrome in schizophrenia patients who are receiving treatment versus antipsychotic naïve, first episode patients from a tertiary care hospital.
    Srivastava S; Bhatia MS; Sharma A
    Asian J Psychiatr; 2018 Jan; 31():121-123. PubMed ID: 29477899
    [No Abstract]   [Full Text] [Related]  

  • 49. Quality of life in schizophrenia: Long-term follow-up in 362 chronic Spanish schizophrenic outpatients undergoing risperidone maintenance treatment.
    Bobes J; Gutiérrez M; Gibert J; Gonzalez M; Herraiz L; Fernández A
    Eur Psychiatry; 1998 May; 13(3):158-63. PubMed ID: 19698620
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cognitive effects of antipsychotics in schizophrenia and relationship to quality of life.
    Kaiser W
    Br J Psychiatry; 2000 Jan; 176():92-3. PubMed ID: 10789338
    [No Abstract]   [Full Text] [Related]  

  • 51. Assessment of quality-of-life outcomes in schizophrenic patients.
    Lehman AF
    Am J Manag Care; 1999 Jul; 5(10 Suppl):S612-9. PubMed ID: 10539496
    [No Abstract]   [Full Text] [Related]  

  • 52. Different antipsychotics produce similar, small improvements in psychosocial functioning at one year in people with schizophrenia.
    Heres S; Kissling W; Leucht S
    Evid Based Ment Health; 2007 Nov; 10(4):112. PubMed ID: 17962661
    [No Abstract]   [Full Text] [Related]  

  • 53. Enhancing Predictive Power: Integrating a Linear Support Vector Classifier with Logistic Regression for Patient Outcome Prognosis in Virtual Reality Therapy for Treatment-Resistant Schizophrenia.
    Hudon A; Beaudoin M; Phraxayavong K; Potvin S; Dumais A
    J Pers Med; 2023 Nov; 13(12):. PubMed ID: 38138887
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Systematic Review on the Effectiveness of Antipsychotic Drugs on the Quality of Life of Patients with Schizophrenia.
    Sampogna G; Di Vincenzo M; Giuliani L; Menculini G; Mancuso E; Arsenio E; Cipolla S; Della Rocca B; Martiadis V; Signorelli MS; Fiorillo A
    Brain Sci; 2023 Nov; 13(11):. PubMed ID: 38002537
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical Outcome Assessment Instruments in Schizophrenia: A Scoping Literature Review with a Focus on the Potential of Patient-reported Outcomes.
    Citrome L; Mychaskiw MA; Cortez A; Opler M; Sopina L; Kotak S
    Innov Clin Neurosci; 2023; 20(4-6):14-33. PubMed ID: 37387708
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systematic Literature Review of Text Messaging Interventions to Promote Medication Adherence Among People With Serious Mental Illness.
    Simon E; Edwards AM; Sajatovic M; Jain N; Montoya JL; Levin JB
    Psychiatr Serv; 2022 Oct; 73(10):1153-1164. PubMed ID: 35959534
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Symptomatic remission affects employment outcomes in schizophrenia patients.
    Wang SP; Wang JD; Chang JH; Wu BJ; Wang TJ; Sun HJ
    BMC Psychiatry; 2020 May; 20(1):219. PubMed ID: 32398138
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 5-HT
    Pogorelov VM; Rodriguiz RM; Cheng J; Huang M; Schmerberg CM; Meltzer HY; Roth BL; Kozikowski AP; Wetsel WC
    Neuropsychopharmacology; 2017 Oct; 42(11):2163-2177. PubMed ID: 28294132
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia.
    Awad G; Ng-Mak D; Rajagopalan K; Hsu J; Pikalov A; Loebel A
    BMC Psychiatry; 2016 Jun; 16():176. PubMed ID: 27245981
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.
    Kruse G; Wong BJ; Duh MS; Lefebvre P; Lafeuille MH; Fastenau JM
    Pharmacoeconomics; 2015 Oct; 33(10):1049-67. PubMed ID: 25963579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.